問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Internal Medicine

Division of Rheumatology

Division of Dermatology

更新時間：2023-09-19

洪偉哲
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

3Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

洪偉哲

List

27Cases

2025-10-01 - 2028-04-30

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2018-06-30 - 2022-06-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated4Sites

2017-08-15 - 2023-11-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated6Sites

賴建志
Taipei Veterans General Hospital

Division of Rheumatology

郭昶甫
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2018-08-01 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

張棋楨
Taipei Medical University Hospital

Division of Rheumatology

2017-05-09 - 2021-05-27

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated5Sites

藍忠亮
China Medical University Hospital-Taipei

未分科

2016-02-29 - 2019-02-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated5Sites

藍忠亮
China Medical University Hospital-Taipei

未分科

2015-09-01 - 2018-12-31

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2021-08-01 - 2025-02-04

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2021-06-30 - 2024-09-02

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2015-09-01 - 2019-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Refractory Subjects With Active Radiographic Axial Spondyloarthritis

  • Condition/Disease

    Active Radiographic Axial Spondyloarthritis

  • Test Drug

    STELARA

Participate Sites
10Sites

Terminated10Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB